Physician profile
Adrian Renaldi
NPI 1275099699
$685.74
in general payments reported to CMS, 2019-2025
14 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $47.25 · 2024: $69.41 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.95 | 2025 | Caplyta |
| Insulet Corporation | $89.48 | 2025 | Omnipod |
| Exact Sciences Corporation | $72.97 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $66.39 | 2024-2025 | Mounjaro, Zepbound |
| Viatris Specialty LLC | $53.08 | 2025 | Yupelri |
| Antares Pharma, INC. | $47.25 | 2022 | |
| Neurocrine Biosciences, INC. | $46.70 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $39.51 | 2025 | Uzedy, Austedo Xr |
| Pfizer INC. | $36.14 | 2025 | |
| Mylan Specialty L.P. | $32.00 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $26.06 | 2025 | Inspire |
| Abbott Laboratories | $21.26 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $19.40 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $17.55 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Renaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.